JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waldherr, C.
Right arrow Articles by Mueller-Brand, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waldherr, C.
Right arrow Articles by Mueller-Brand, J.
Journal of Nuclear Medicine Vol. 43 No. 5 610-616
© 2002 by Society of Nuclear Medicine

Clinical Investigations

Tumor Response and Clinical Benefit in Neuroendocrine Tumors After 7.4 GBq 90Y-DOTATOC

Christian Waldherr, MD1, Miklos Pless, MD2, Helmut R. Maecke, PhD3, Tilmann Schumacher, MD1, Armin Crazzolara, MD1, Egbert U. Nitzsche, MD1, Andreas Haldemann, MD4 and Jan Mueller-Brand, MD1

1 PET Center, Institute of Nuclear Medicine, University Hospital, University of Basel, Basel, Switzerland
2 Department of Oncology, University Hospital, University of Basel, Basel, Switzerland
3 Institute of Radiological Chemistry, University Hospital, University of Basel, Basel, Switzerland
4 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

The aim of this prospective phase II study was to evaluate the tumor response of neuroendocrine tumors to high-dose targeted irradiation with 7.4 GBq/m2 of the radiolabeled somatostatin analog 90Y-1,4,7,10-tetra-azacyclododecan-4,7,10-tricarboxy-methyl-1-yl-acetyl-D-Phe-Tyr3-octreotide (DOTATOC). In addition, we investigated the clinical benefit of 90Y-DOTATOC regarding the malignant carcinoid syndrome and tumor-associated pain. Methods: Thirty-nine patients (mean age, 55 y) with progressive neuroendocrine gastroenteropancreatic and bronchial tumors were included. The treatment consisted of 4 equal intravenous injections of a total of 7.4 GBq/m2 90Y-DOTATOC, administered at intervals of 6 wk. After each treatment cycle, a standardized clinical benefit assessment using the National Cancer Institute grading criteria (NCI-CTC) was performed. Results: The objective response rate according to World Health Organization (WHO) criteria was 23%. For endocrine pancreatic tumors (13 patients), the objective response rate was 38%. Complete remissions were found in 5% (2/39), partial remissions in 18% (7/39), stable disease in 69% (27/39), and progressive disease in 8% (3/39). A significant reduction of clinical symptoms could be found in 83% of patients with diarrhea, in 46% of patients with flush, in 63% of patients with wheezing, and in 75% of patients with pellagra. The overall clinical benefit was 63%. All responses (both clinical benefit and WHO response) were ongoing for the duration of follow-up (median, 6 mo; range, 2–12 mo). Side effects were grade 3 or 4 (NCI-CTC) lymphocytopenia in 23%, grade 3 anemia in 3%, and grade 2 renal insufficiency in 3%. Conclusion: High-dose targeted radiotherapy with 7.4 GBq/m2 90Y-DOTATOC is a well-tolerated treatment for neuroendocrine tumors, with remarkable clinical benefit and objective response.

Key Words: radionuclide therapy • radiopeptide • somatostatin • octreotide • neuroendocrine tumor • 90Y-DOTATOC




This article has been cited by other articles:


Home page
 JNMHome page
B. W. Wessels, M. W. Konijnenberg, R. G. Dale, H. B. Breitz, M. Cremonesi, R. F. Meredith, A. J. Green, L. G. Bouchet, A. B. Brill, W. E. Bolch, et al.
MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy
J. Nucl. Med., November 1, 2008; 49(11): 1884 - 1899.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Kwekkeboom, W. W. de Herder, B. L. Kam, C. H. van Eijck, M. van Essen, P. P. Kooij, R. A. Feelders, M. O. van Aken, and E. P. Krenning
Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
J. Clin. Oncol., May 1, 2008; 26(13): 2124 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Khanna, D. Bushnell, and M. S. O'Dorisio
Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
Oncologist, April 1, 2008; 13(4): 382 - 389.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H. R. Macke, J. Muller-Brand, and M. A. Walter
Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial
Clin. Cancer Res., November 15, 2007; 13(22): 6696 - 6702.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans
Targeted therapy in nuclear medicine current status and future prospects
Ann. Onc., November 1, 2007; 18(11): 1782 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Wicki, D. Wild, D. Storch, C. Seemayer, M. Gotthardt, M. Behe, S. Kneifel, M. J. Mihatsch, J.-C. Reubi, H. R. Macke, et al.
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
Clin. Cancer Res., June 15, 2007; 13(12): 3696 - 3705.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. H Kulke
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Korner, M. Stockli, B. Waser, and J. C. Reubi
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
J. Nucl. Med., May 1, 2007; 48(5): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G Butturini, R Bettini, E Missiaglia, W Mantovani, I Dalai, P Capelli, M Ferdeghini, P Pederzoli, A Scarpa, and M Falconi
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1213 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Wild, M. Behe, A. Wicki, D. Storch, B. Waser, M. Gotthardt, B. Keil, G. Christofori, J. C. Reubi, and H. R. Macke
[Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting
J. Nucl. Med., December 1, 2006; 47(12): 2025 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli
Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. E. Lantry, E. Cappelletti, M. E. Maddalena, J. S. Fox, W. Feng, J. Chen, R. Thomas, S. M. Eaton, N. J. Bogdan, T. Arunachalam, et al.
177Lu-AMBA: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer
J. Nucl. Med., July 1, 2006; 47(7): 1144 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Capello, E. P. Krenning, B. F. Bernard, W. A.P. Breeman, J. L. Erion, and M. de Jong
Anticancer Activity of Targeted Proapoptotic Peptides
J. Nucl. Med., January 1, 2006; 47(1): 122 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G A Kaltsas, D Papadogias, P Makras, and A B Grossman
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. M. Verwijnen, E. P. Krenning, R. Valkema, J. G.M. Huijmans, and M. de Jong
Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide
J. Nucl. Med., December 1, 2005; 46(12): 2057 - 2060.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. K. G. McStay, D. Maudgil, M. Williams, J. M. Tibballs, A. F. Watkinson, M. E. Caplin, and J. R. Buscombe
Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial 90Y-DOTA-Lanreotide as Effective Palliative Therapy
Radiology, November 1, 2005; 237(2): 718 - 726.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. de Jong, R. Barone, E. Krenning, B. Bernard, M. Melis, T. Visser, M. Gekle, T. E. Willnow, S. Walrand, F. Jamar, et al.
Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPA-Octreotide
J. Nucl. Med., October 1, 2005; 46(10): 1696 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Korner, G. M. Hayes, R. Rehmann, A. Zimmermann, H. Friess, L. J. Miller, and J. C. Reubi
Secretin Receptors in Normal and Diseased Human Pancreas: Marked Reduction of Receptor Binding in Ductal Neoplasia
Am. J. Pathol., October 1, 2005; 167(4): 959 - 968.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Storch, M. Behe, M. A. Walter, J. Chen, P. Powell, R. Mikolajczak, and H. R. Macke
Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
J. Nucl. Med., September 1, 2005; 46(9): 1561 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. Forrer, H. Uusijarvi, D. Storch, H. R. Maecke, and J. Mueller-Brand
Treatment with 177Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After Treatment with 90Y-DOTATOC
J. Nucl. Med., August 1, 2005; 46(8): 1310 - 1316.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al.
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Gut, June 1, 2005; 54(suppl_4): iv1 - iv16.
[Full Text] [PDF]

Home page
 JNMHome page
Y. Miao, N. K. Owen, D. R. Fisher, T. J. Hoffman, and T. P. Quinn
Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
J. Nucl. Med., January 1, 2005; 46(1): 121 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Zitzmann, W. Mier, A. Schad, R. Kinscherf, V. Askoxylakis, S. Kramer, A. Altmann, M. Eisenhut, and U. Haberkorn
A New Prostate Carcinoma Binding Peptide (DUP-1) for Tumor Imaging and Therapy
Clin. Cancer Res., January 1, 2005; 11(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. de Jong, W. A.P. Breeman, R. Valkema, B. F. Bernard, and E. P. Krenning
Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
J. Nucl. Med., January 1, 2005; 46(1_suppl): 13S - 17S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. J. Kwekkeboom, J. Mueller-Brand, G. Paganelli, L. B. Anthony, S. Pauwels, L. K. Kvols, T. M. O'Dorisio, R. Valkema, L. Bodei, M. Chinol, et al.
Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
J. Nucl. Med., January 1, 2005; 46(1_suppl): 62S - 66S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Valkema, S. A. Pauwels, L. K. Kvols, D. J. Kwekkeboom, F. Jamar, M. de Jong, R. Barone, S. Walrand, P. P.M. Kooij, W. H. Bakker, et al.
Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate
J. Nucl. Med., January 1, 2005; 46(1_suppl): 83S - 91S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Pauwels, R. Barone, S. Walrand, F. Borson-Chazot, R. Valkema, L. K. Kvols, E. P. Krenning, and F. Jamar
Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogs
J. Nucl. Med., January 1, 2005; 46(1_suppl): 92S - 98S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Barone, F. Borson-Chazot, R. Valkema, S. Walrand, F. Chauvin, L. Gogou, L. K. Kvols, E. P. Krenning, F. Jamar, and S. Pauwels
Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship
J. Nucl. Med., January 1, 2005; 46(1_suppl): 99S - 106S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. J.M. Teunissen, D. J. Kwekkeboom, P. P.M. Kooij, W. H. Bakker, and E. P. Krenning
Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma
J. Nucl. Med., January 1, 2005; 46(1_suppl): 107S - 114S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. R. Maecke, M. Hofmann, and U. Haberkorn
68Ga-Labeled Peptides in Tumor Imaging
J. Nucl. Med., January 1, 2005; 46(1_suppl): 172S - 178S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Korner, B. Waser, and J. C. Reubi
High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia
Clin. Cancer Res., December 15, 2004; 10(24): 8426 - 8433.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Schmitt, P. Bernhardt, O. Nilsson, H. Ahlman, L. Kolby, H. R. Maecke, and E. Forssell-Aronsson
Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-Octreotate in an Animal Model
J. Nucl. Med., September 1, 2004; 45(9): 1542 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J.M. Teunissen, D. J. Kwekkeboom, and E. P. Krenning
Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotate
J. Clin. Oncol., July 1, 2004; 22(13): 2724 - 2729.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. de Jong, R. Valkema, A. van Gameren, H. van Boven, A. Bex, E. P. van de Weyer, J. D. Burggraaf, M. Korner, J.-C. Reubi, and E. P. Krenning
Inhomogeneous Localization of Radioactivity in the Human Kidney After Injection of [111In-DTPA]Octreotide
J. Nucl. Med., July 1, 2004; 45(7): 1168 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. W. Konijnenberg, M. Bijster, E. P. Krenning, and M. de Jong
A Stylized Computational Model of the Rat for Organ Dosimetry in Support of Preclinical Evaluations of Peptide Receptor Radionuclide Therapy with 90Y, 111In, or 177Lu
J. Nucl. Med., July 1, 2004; 45(7): 1260 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Bushnell, T. O'Dorisio, Y. Menda, T. Carlisle, P. Zehr, M. Connolly, M. Karwal, S. Miller, S. Parker, and H. Bouterfa
Evaluating the Clinical Effectiveness of 90Y-SMT 487 in Patients with Neuroendocrine Tumors
J. Nucl. Med., October 1, 2003; 44(10): 1556 - 1560.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. J. Hofland and S. W. J. Lamberts
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Endocr. Rev., February 1, 2003; 24(1): 28 - 47.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. d. Jong and E. Krenning
New Advances in Peptide Receptor Radionuclide Therapy
J. Nucl. Med., May 1, 2002; 43(5): 617 - 620.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.